RAPT Therapeutics, Inc.(RAPT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
RAPT Stock Analysis & AI Quality Score
AI stock analysis and institutional research for RAPT Therapeutics, Inc. (RAPT), a Healthcare sector company. RAPT is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q3 2025), RAPT Therapeutics, Inc. reports net income of $-17.6M, free cash flow of $-12.5M. Top institutional holders of RAPT by reported 13-F value include Medicxi Ventures Management (Jersey) Ltd, TCG Crossover Management,, FCPM III SERVICES B.V., based on the most recent SEC filings. RAPT trades on the Nasdaq exchange and files with the SEC under CIK 1673772. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RAPT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RAPT Therapeutics, Inc. directly from SEC EDGAR. RAPT Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 3 and 41 since 2021, currently 4.6 — a declining long-term trajectory across 12 quarterly and live scoring snapshots.
Net Income
Q3 2025
$-17.6M
Free Cash Flow
Q3 2025
$-12.5M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
-11.2% YoYOperating Income
-7.1% YoYEPS (Diluted)
-4.6% YoYTotal Assets
+38.7% YoYOp. Cash Flow
+14.2% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue | — | $0.00 -100.0% | $1.5M -60.0% | $3.8M -24.4% | $5.0M | — |
| Net Income | $-129.9M -11.2% | $-116.8M -39.3% | $-83.8M -21.1% | $-69.2M -30.8% | $-52.9M -46.3% | $-36.1M |
| Operating Income | $-136.1M -7.1% | $-127.1M -48.1% | $-85.8M -24.0% | $-69.2M -30.1% | $-53.2M -44.0% | $-36.9M |
| EPS (Diluted) | $-3.19 -4.6% | $-3.05 -18.2% | $-2.58 -2.0% | $-2.53 | — | — |
| Total Assets | $240.3M +38.7% | $173.3M -34.9% | $266.2M +34.0% | $198.6M +67.0% | $119.0M +70.9% | $69.6M |
| Operating Cash Flow | $-83.3M +14.2% | $-97.0M -37.1% | $-70.8M -16.0% | $-61.0M -50.7% | $-40.5M -22.9% | $-33.0M |
Get alerted when RAPT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for RAPT Therapeutics, Inc. including:
Top Institutional Holders of RAPT
Medicxi Ventures Management (Jersey) Ltd
$94.6M2,794,000 shTCG Crossover Management, LLC
$87.5M2,582,408 shFCPM III SERVICES B.V.
$62.1M1,833,333 shORBIMED ADVISORS LLC
$55.6M1,642,891 shRTW INVESTMENTS, LP
$55.5M1,637,165 shForesite Capital Management VI LLC
$52.9M1,562,500 shSiren, L.L.C.
$46.6M1,375,000 shVANGUARD GROUP INC
$40.2M1,186,791 shADAR1 Capital Management, LLC
$34.5M1,019,358 shFrazier Life Sciences Management, L.P.
$33.3M983,333 sh
| Fund | Value | Shares |
|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | $94.6M | 2,794,000 |
| TCG Crossover Management, LLC | $87.5M | 2,582,408 |
| FCPM III SERVICES B.V. | $62.1M | 1,833,333 |
| ORBIMED ADVISORS LLC | $55.6M | 1,642,891 |
| RTW INVESTMENTS, LP | $55.5M | 1,637,165 |
| Foresite Capital Management VI LLC | $52.9M | 1,562,500 |
| Siren, L.L.C. | $46.6M | 1,375,000 |
| VANGUARD GROUP INC | $40.2M | 1,186,791 |
| ADAR1 Capital Management, LLC | $34.5M | 1,019,358 |
| Frazier Life Sciences Management, L.P. | $33.3M | 983,333 |
More Healthcare Companies
View all Healthcare →Put RAPT on your watchlist
Track score changes the day RAPT Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is RAPT a good stock to buy?
13F Pro's AI-powered analysis of RAPT Therapeutics, Inc. (RAPT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RAPT are available on the RAPT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own RAPT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RAPT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of RAPT Therapeutics, Inc.'s investment landscape.